International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 1

India | Pharmacotherapeutics | Volume 11 Issue 6, June 2022 | Pages: 1369 - 1369


Will Dostarlimab Become the New Rectal Cancer Drug of Choice?

Motupalli Sankeerth Kumar, Ponnaluri Lalitha, Seelam Victor John Wilson

Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.

Keywords: Dostarlimab, Rectal cancer, new drug of choice

How to Cite?: Motupalli Sankeerth Kumar, Ponnaluri Lalitha, Seelam Victor John Wilson, "Will Dostarlimab Become the New Rectal Cancer Drug of Choice?", Volume 11 Issue 6, June 2022, International Journal of Science and Research (IJSR), Pages: 1369-1369, https://www.ijsr.net/getabstract.php?paperid=SR22617214828, DOI: https://dx.doi.org/10.21275/SR22617214828


Download Article PDF


Rate This Article!

Received Comments

No approved comments available.


Top